SCHEMBL9623780

SCHEMBL9623780

CC(=O)CCCCCCCCCCN

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 6/20 1.00
LMNA P02545 3/20 0.59
ALDH1A1 P00352 2/20 0.59
THRB P10828 2/20 0.59
KMT2A Q03164 2/20 0.59
MEN1 O00255 1/20 0.59
PLG P00747 1/20 0.59
ALOX15 P16050 1/20 0.59
SLC6A2 P23975 1/20 0.59
RECQL P46063 1/20 0.59
SLC6A3 Q01959 1/20 0.59
CYP2D6 P10635 1/20 0.55
NFKB1 P19838 1/20 0.55
BLM P54132 3/20 0.52
NPSR1 Q6W5P4 2/20 0.52
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA3 P07451 2/20 0.44
CA4 P22748 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6420548 1.00 PAOX (1.00) PAOXLMNAALDH1A1THRBKMT2A
SCHEMBL13082344 1.00 PAOX (1.00) PAOXLMNAALDH1A1THRBKMT2A
SCHEMBL3318566 1.00 PAOX (1.00) PAOXLMNAALDH1A1THRBKMT2A
SCHEMBL12658620 1.00 PAOX (1.00) PAOXLMNAALDH1A1THRBKMT2A
SCHEMBL806164 1.00
SCHEMBL23872982 1.00 PAOX (1.00) PAOXLMNAALDH1A1THRBKMT2A
SCHEMBL18726287 1.00 PAOX (1.00) PAOXLMNAALDH1A1THRBKMT2A
SCHEMBL16297742 1.00 PAOX (1.00) PAOXLMNAALDH1A1THRBKMT2A
SCHEMBL18533504 1.00 PAOX (1.00) PAOXLMNAALDH1A1THRBKMT2A
Water SCHEMBL5510156 0.97 PAOX (0.95) PAOXLMNAALDH1A1THRBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364243-A1 CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2023-11-16 US disclosed
WO-2023097038-A1 CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF FULL-LIFE TECHNOLOGIES U.S. INC. (US) 2023-06-01 WO disclosed
US-10786576-B2 Fatty acids and their use in conjugation to biomolecules NOVARTIS AG (CH) 2020-09-29 US disclosed
US-20170137814-A1 ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT 2017-05-18 US disclosed
EP-0239954-B1 A METHOD OF SYNTHESIZING ACID AMIDE JAPAN TOBACCO INC. (JP) 1992-01-22 EP disclosed
EP-0239954-A2 A method of synthesizing acid amide JAPAN TOBACCO INC. (JP) 1987-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230364243-A1 CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS ADRM1, MYC, SKP2 PAOX 1884/4885LMNA 2898/4885ALDH1A1 3675/4885
US-10786576-B2 Fatty acids and their use in conjugation to biomolecules FABP1, FABP2, FABP3 PAOX 912/4885LMNA 1424/4885ALDH1A1 907/4885
US-20170137814-A1 ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES APOL1, APOB, LDLR PAOX 578/4885LMNA 2479/4885ALDH1A1 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.